H2N3 virus trial underway – a heads-up for POC diagnostics?
This article was originally published in Clinica
The US National Institute of Allergy and Infectious Diseases (NIAID) is launching a trial of a human vaccine for the A-H2N3 influenza virus. The initiative suggests renewed concerns around the potential transmissibility of H2N3 to humans and, more generally, the need for tighter diagnostic surveillance across the growing patchwork of influenza strains.
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.